Retatrutide's clinical trial numbers are genuinely staggering. Up to 29% body weight loss at 68 weeks — that's approaching gastric bypass results without surgery. For a 250-pound person, that's roughly 72 pounds. The glucagon component appears to boost calorie burning and fat metabolism, potentially preserving more lean muscle mass than current GLP-1s.
Latest results (March 2026) in type 2 diabetes showed HbA1c reduction of 1.7–2.0% and weight loss up to 17% — exceeding Mounjaro's results in comparable trials.
The Math on Waiting
Retatrutide is in phase 3 trials. Optimistically: FDA filing in late 2027, approval in 2028. That's 18–24 months from now. If you started tirzepatide today, you could lose 20–22% of your body weight in that same timeframe. A 250-pound person starting now could weigh 195–200 lbs by the time retatrutide launches.
Then you could switch to retatrutide for additional loss if desired. The ATTAIN-MAINTAIN data shows that injectable-to-oral transitions work. Injectable-to-injectable transitions are even smoother.
The Pipeline Isn't a Guarantee
Phase 3 trials sometimes fail. FDA approval isn't automatic. Launch dates slip. For every drug that makes it to market, dozens don't. Planning your health around a drug that doesn't exist yet is a gamble. Planning around drugs that do exist is medicine.
What's Available Right Now
| Drug | Targets | Avg Weight Loss | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | ~15% | Available now |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~22% | Available now |
| Retatrutide | GLP-1 + GIP + Glucagon | ~29% | Phase 3 trials |
Embody
Don't wait for the perfect drug. Start losing weight today with proven GLP-1 treatment. Transition to newer options when they become available.
Compare Now →Direct Meds
Online consultation, physician review, medication shipped directly. Direct Meds removes friction from getting started.
Compare Now →